$MBIO Cashflow Statement | Understand Stock

$MBIO

$0.36 +$0.00 (0.17%) Close

$MBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows from Operating Activities:
Net loss
Issuance of common shares - Equity fee on at-the-market offering to Fortress Biotech
Issuance of common shares - Equity fee on Public Offering to Fortress Biotech
Common shares issuable - Equity fee on at-the-market offering to Fortress Biotech
Common shares issuable - Equity fee on Registered Direct Offering to Fortress Biotech
Common shares issuable - Annual Stock Dividend to Fortress Biotech
Issuance of common shares - Equity fee on note payable to Fortress Biotech
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of common shares - equity fee on equity offerings to Fortress Biotech
Common shares issuable - Equity fee on at-the-market offering to Fortress Biotech
Common shares issuable - Equity fee on Registered Direct Offering to Fortress Biotech
Common shares issuable - Annual Stock Dividend to Fortress Biotech
Research and development - licenses acquired
Issuance of common shares - Equity fee to Fortress Biotech on note payable
Stock-based compensation expenses
Depreciation expense
Amortization of debt discount
Amortization of operating lease right-of-use assets
Settlement of payables
Loss on disposal of property and equipment
Asset impairment
Gain on sale of property and equipment
Loss on extinguishment of debt
Gain on lease termination
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Other receivables
Related Party
Non related party
Total other receivables
Accounts payable and accrued expenses
Payable and accrued expenses - related party
Deferred income
Lease liabilities

Net cash used in operating activities

Cash Flows from Investing Activities:
Purchase of research and development licenses
Proceeds from the sale of property and equipment
Purchase of fixed assets
Net cash from investing activities
Cash Flows from Financing Activities:
Payment of debt
Proceeds from issuance of common shares - Equity Offerings
Offering costs for the issuance of common shares - Equity Offerings
Repayment of notes payable
Proceeds from issuance of common shares, net of offering costs - equity offering
Proceeds from issuance of common shares, net of offering costs - At-the-Market offering
Offering costs for the issuance of common shares - At-the-Market Offering
Proceeds from debt issuance
Proceeds from warrant exercises
Proceeds from issuance of common shares under ESPP
Net cash provided by financing activities

Net change in cash and cash equivalents
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
Cash paid for interest
Supplemental disclosure of noncash activities:
Fixed assets (acquired but not paid)
Issuance of common shares - Founders Agreement and equity fee to Fortress
Research and development licenses included in accounts payable and accrued expenses
Note payable final payment fee (incurred but not paid)
Issuance of warrants - note payable
Lease liabilities arising from obtaining right-of-use assets
Offering costs for the issuance of common shares - At-the-Market Offering, in accounts payable and accrued expenses

Comments